Psyence Biomed Closes $2M Private Placement
Psyence Biomedical Ltd., a Nasdaq-listed biotechnology company (Nasdaq: PBM), recently finalized a private placement, raising approximately $2 million before...
Vor Bio Announces $55.6M Private Placement
Vor Bio, a clinical-stage cell and genome engineering company, has secured approximately $55.6 million in gross proceeds through a...
Ikena Oncology and Inmagene Merger Announcement
Ikena Oncology and Inmagene Biopharmaceuticals have entered into a definitive merger agreement. The combined company will focus on developing...
PainReform Delivers Phase 3 Trial Update on PRF-110
PainReform Ltd. (Nasdaq: PRFX), a clinical-stage pharmaceutical company specializing in reformulating existing therapies, has provided an update on its...
Selonabant Shows Promise in Acute Cannabis Toxicity in Children
Anebulo Pharmaceuticals has announced positive regulatory feedback from the FDA and the closure of a capital raise. The FDA...
Axena Health Starts UI Treatment Patient Enrollment at Two Nigerian Sites
Axena Health has launched a feasibility study in Nigeria to explore a new treatment for female incontinence, combining the...
Therapeutic Blood Thinners Reduce COVID-19 Mortality
A new international study, analyzing 22 clinical trials and 11,000 patients across 21 countries, found that therapeutic doses of...
Daiichi and AstraZeneca Datopotamab Deruxtecan Application Withdrawn from EU
Daiichi Sankyo and AstraZeneca have withdrawn their EU marketing authorization application for datopotamab deruxtecan (Dato-DXd) in locally advanced or...
Exicure & GPCR Therapeutics Partner to Fuel Biotech Growth
Exicure, Inc. signed a Memorandum of Understanding with GPCR Therapeutics to acquire GPCR USA, a subsidiary specializing in G...
FDA Approves Trikafta for Additional Cystic Fibrosis Variants
The FDA has expanded the approval of Vertex Pharmaceuticals’ TRIKAFTA, a cystic fibrosis (CF) treatment, to include individuals aged...